Clearside Biomedical, Inc. (CLSDQ)
OTCMKTS
· Delayed Price · Currency is USD
0.7900
-0.1100 (-12.22%)
At close: Dec 5, 2025
Clearside Biomedical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 3.33 | 1.66 | 8.23 | 1.33 | 29.58 | 7.89 | Upgrade
|
| Revenue Growth (YoY) | -56.78% | -79.77% | 519.89% | -95.51% | 274.65% | 263.28% | Upgrade
|
| Cost of Revenue | 0.4 | 0.15 | 0.36 | 0.2 | - | - | Upgrade
|
| Gross Profit | 2.93 | 1.52 | 7.87 | 1.12 | 29.58 | 7.89 | Upgrade
|
| Selling, General & Admin | 12.67 | 11.81 | 11.87 | 11.77 | 11.67 | 10.76 | Upgrade
|
| Research & Development | 13.22 | 18.59 | 20.85 | 19.63 | 18.54 | 15.07 | Upgrade
|
| Operating Expenses | 25.89 | 30.4 | 32.72 | 31.4 | 30.2 | 25.83 | Upgrade
|
| Operating Income | -22.96 | -28.88 | -24.84 | -30.28 | -0.63 | -17.94 | Upgrade
|
| Interest Expense | -10.58 | -9.78 | -9.36 | -3.34 | - | -0.34 | Upgrade
|
| Interest & Investment Income | 0.7 | 1.46 | 1.72 | 0.67 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 7.56 | 2.85 | - | - | 0.01 | 0.06 | Upgrade
|
| EBT Excluding Unusual Items | -25.28 | -34.35 | -32.49 | -32.95 | -0.62 | -18.21 | Upgrade
|
| Other Unusual Items | - | - | - | - | 1 | - | Upgrade
|
| Pretax Income | -25.28 | -34.35 | -32.49 | -32.95 | 0.38 | -18.21 | Upgrade
|
| Net Income | -26 | -34.35 | -32.49 | -32.95 | 0.38 | -18.21 | Upgrade
|
| Net Income to Common | -26 | -34.35 | -32.49 | -32.95 | 0.38 | -18.21 | Upgrade
|
| Shares Outstanding (Basic) | 5 | 5 | 4 | 4 | 4 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 5 | 4 | 4 | 4 | 3 | Upgrade
|
| Shares Change (YoY) | 9.72% | 19.41% | 2.66% | 0.50% | 28.81% | 21.84% | Upgrade
|
| EPS (Basic) | -5.05 | -6.98 | -7.88 | -8.21 | 0.10 | -5.87 | Upgrade
|
| EPS (Diluted) | -5.05 | -6.98 | -7.88 | -8.21 | 0.10 | -5.87 | Upgrade
|
| Free Cash Flow | -21.75 | -25.68 | -19.91 | -13.61 | -10.73 | -13.18 | Upgrade
|
| Free Cash Flow Per Share | -4.22 | -5.22 | -4.83 | -3.39 | -2.69 | -4.25 | Upgrade
|
| Gross Margin | 88.07% | 91.05% | 95.68% | 84.63% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -689.76% | -1735.70% | -302.02% | -2281.61% | -2.12% | -227.20% | Upgrade
|
| Profit Margin | -780.89% | -2064.42% | -394.91% | -2482.82% | 1.27% | -230.68% | Upgrade
|
| Free Cash Flow Margin | -653.23% | -1542.97% | -242.06% | -1025.70% | -36.29% | -166.90% | Upgrade
|
| EBITDA | -22.63 | -28.66 | -24.78 | -30.13 | -0.45 | -17.76 | Upgrade
|
| EBITDA Margin | - | - | - | - | -1.52% | -224.92% | Upgrade
|
| D&A For EBITDA | 0.33 | 0.23 | 0.07 | 0.15 | 0.18 | 0.18 | Upgrade
|
| EBIT | -22.96 | -28.88 | -24.84 | -30.28 | -0.63 | -17.94 | Upgrade
|
| EBIT Margin | - | - | - | - | -2.12% | -227.20% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.